POULVAC® ST: FOR REDUCED SALMONELLA RISK1-5
When it comes to Salmonella management, taking a prevention-oriented approach is helping reduce contamination in chickens, resulting in more valued chicken and eggs.
Poulvac® ST from Zoetis is a modified-live vaccine that helps poultry companies reduce their overall Salmonella load at critical points in poultry supply chains. It provides broad-spectrum protection against several Salmonella serotypes within groups B, C and D by reducing Salmonella colonization of internal organs and ceca.1-5
Proven advantages under commercial broiler conditions
Poulvac ST has demonstrated impact where it matters most — in the processing plant. In a recent broiler field study comparing millions of birds over a 14-week span, Poulvac ST helped provide the following advantages relative to unvaccinated controls: 6
2.5 times reduction in the percentage of Salmonella-positive broiler rinsates at rehang (16.2% vs. 6.4%).
3 times reduction of the recovery of Group B and Group C serotypes.
Vaccinated birds also held a feed conversion advantage.
Protection without detection
While Poulvac ST stimulates immunity that reduces Salmonella colonization, the vaccine’s construction helps helps ensure it will not be detected by U.S. Department of Agriculture inspectors. Therefore, the vaccine's use will not lead to false positives in the processing plant.
This is because Poulvac ST contains a gene-deleted aroA mutant that causes the vaccine to stop replicating once aromatic amino acids are no longer available. So, while the vaccine strain is recoverable at up to two weeks post-vaccination7,8 the vaccine isolate will not persist in the bird, on the bird or in the environment.
Part of an integrated Salmonella management approach
Poulvac ST is part of a comprehensive offering of preharvest and post-harvest interventions from Zoetis, all backed by decades of hatchery, veterinary and processing expertise.
Reducing Salmonella colonization in commercial layers
Poulvac ST helps stimulate cell-mediated immunity, making it an effective tool for priming pullet immune systems to maximize the opportunity for inactivated S. enteritidis vaccines to be successful. Poulvac ST has demonstrated a 50% reduction of S. kentucky, S. enteritidis, S. heidelberg, S. typhimurium and S. hadar incidence, as measured by positive samples collected from internal organs.1-5
Poulvac ST® is part of the Poulvac Salmonella portfolio, which also includes Poulvac SE and Poulvac SE-ND-IB, to give egg producers a comprehensive set of tools to help prevent Salmonella colonization. These vaccines are supported by account managers and veterinarians dedicated to commercial layer production, providing on-farm services for promoting proper vaccination administration and measuring vaccine performance.
Contact your Zoetis representative to review and optimize your integrated Salmonella management program.